REG - Avacta Group PLC - Avacta to Present at Theranostics FAP Summit

AvactaAnnouncement

31/10/2022 13:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221031:nRSe7742Ea&default-theme=true

RNS Number : 7742E  Avacta Group PLC  31 October 2022

 

 

 

 

 

 

31 October 2022

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Avacta to Present at Virtual Theranostics FAP Summit

 

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company
developing innovative cancer therapies and powerful diagnostics based on its
proprietary Affimer(®) and pre|CISION™ platforms, announces that it will be
presenting at the Theranostics FAP Summit, organised by the International
Centers for Precision Oncology Foundation, being held on 5 November 2022.

 

The online meeting will feature world-renowned experts in the biology of
Fibroblast Activation Protein (FAP), which is highly expressed in
cancer-associated fibroblasts (CAF) across many tumour types. Representatives
from academia and industry will take a deep dive into the topic of FAP, its
history and role in the biology of disease, the current state of research, and
future applications in both diagnostics and therapeutic areas.

 

AVA6000 is a form of the generic chemotherapy doxorubicin that has been
modified using Avacta's pre|CISION technology so that it is activated by FAP,
predominantly in the tumour, with the aim of sparing healthy tissue from
exposure and improving the safety, tolerability and efficacy of the drug.
Avacta's presentation, to be given by Dr Fiona Maclaughlin, Chief Scientific
Officer of the Therapeutics division, will highlight the pre-clinical
development of AVA6000.

 

No new information will be shared as part of the presentation.

 

Title: Pre-clinical Development of AVA6000 - a FAP targeted chemotherapeutic
agent in Phase I

Day/Date: Saturday, 5 November 2022

Time: 17:30 - 17:45 CET

Session number: VI

-Ends-

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                         www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Broker)               Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland   www.stifel.com (http://www.stifel.com/)

 FTI Consulting (Financial Media and IR)                         Tel: +44(0) 203 727 1000

 Simon Conway / Alex Shaw / George Kendrick                      Avacta.LS@fticonsulting.com (mailto:Avacta.LS@fticonsulting.com)

 Zyme Communications (Trade and Regional Media)                  Tel: +44 (0)7891 477 378

 Lily Jeffery                                                    lily.jeffery@zymecommunications.com

                                                               (mailto:katie.odgaard@zymecommunications.com)

 

About Avacta Group plc - https://www.avacta.com (https://www.avacta.com/)

 

Avacta Group is developing novel cancer immunotherapies and powerful
diagnostics based on its two proprietary platforms - Affimer(®) biologics
and pre|CISION™ tumour targeted chemotherapies.

 

The Affimer(®) platform is an alternative to antibodies and is derived from
a small human protein. Affimer technology has been designed to address many of
the negative issues of antibodies, principally: the time taken to generate new
antibodies, the reliance on an animal's immune response; poor specificity in
many cases; in addition to, the complexity and high cost of manufacture.
Despite these shortcomings, antibodies currently dominate markets, such as
diagnostics and therapeutics, which are worth in excess of $100bn.

 

Avacta's pre|CISION™ targeted chemotherapy platform is designed to
selectively release active chemotherapy in FAP rich tumour tissue to limit the
systemic exposure that causes damage to healthy tissues, and thereby aims to
improve the overall safety and therapeutic potential of these powerful
anti-cancer treatments.

 

The Avacta Group comprises two divisions: The therapeutics development
activities are based in London, UK and a separate diagnostics business unit
is based in Wetherby, UK. The Group is generating near-term revenues from
Affimer(®) reagents for diagnostics, bioprocessing and research.

 

Avacta's Diagnostics Division is developing an in-house pipeline of
Affimer-based diagnostic assays, including the AffiDX(®) SARS-CoV-2 Lateral
Flow Rapid Antigen Test, and works with partners world-wide to develop bespoke
Affimer(®) reagents for third party products.

 

Avacta's Therapeutics Division is working to generate more tolerable and
durable treatments for oncology patients who do not respond to existing
therapies. By combining its two proprietary platforms the Group is building a
wholly owned pipeline of clinically differentiated cancer therapies. In
2021 Avacta transitioned to become a clinical stage biopharmaceutical
company, when it commenced a phase I trial in patients with locally advanced
or metastatic selected solid tumours. The study was a first-in-human, open
label, dose-escalation and expansion study of the Group's lead pre|CISION™
prodrug, AVA6000 (a pro-doxorubicin).

 

Avacta has established drug development partnerships with pharma and biotech,
including a multi-target deal with LG Chem worth up to $400m, a joint venture
in South Korea with Daewoong Pharmaceutical focused on cell and gene
therapies incorporating Affimer immune-modulators and a recent license
agreement with Point Biopharma for them to develop radiopharmaceuticals based
on the pre|CISION™ platform.

 

To register for news alerts by email go
to www.avacta.com/investor-news-email-alerts
(http://www.avacta.com/investor-news-email-alerts)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMBBJTMTTJBRT